AR112531A1 - CANCER TREATMENT USING A BLAUTIA STRAIN - Google Patents

CANCER TREATMENT USING A BLAUTIA STRAIN

Info

Publication number
AR112531A1
AR112531A1 ARP180102449A AR112531A1 AR 112531 A1 AR112531 A1 AR 112531A1 AR P180102449 A ARP180102449 A AR P180102449A AR 112531 A1 AR112531 A1 AR 112531A1
Authority
AR
Argentina
Prior art keywords
cancer treatment
blautia strain
blautia
strain
therapeutic agents
Prior art date
Application number
Other languages
Spanish (es)
Original Assignee
Evelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evelo Biosciences Inc filed Critical Evelo Biosciences Inc
Publication of AR112531A1 publication Critical patent/AR112531A1/en

Links

Landscapes

  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos y composiciones relacionados con la cepa A de Blautia útiles como agentes terapéuticos.Blautia strain A related methods and compositions useful as therapeutic agents.

ARP180102449 2017-08-29 2018-08-29 CANCER TREATMENT USING A BLAUTIA STRAIN AR112531A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762551554P 2017-08-29 2017-08-29

Publications (1)

Publication Number Publication Date
AR112531A1 true AR112531A1 (en) 2019-11-06

Family

ID=68732050

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180102449 AR112531A1 (en) 2017-08-29 2018-08-29 CANCER TREATMENT USING A BLAUTIA STRAIN

Country Status (1)

Country Link
AR (1) AR112531A1 (en)

Similar Documents

Publication Publication Date Title
CL2018001152A1 (en) Compositions and methods for cancer treatment
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
CY1124131T1 (en) ANTI-RTK7 ANTIBODY-DRUG CONJUGATS
AR113881A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISORDERS USING THE BLAUTIA STRAIN
MD3209310T2 (en) Compositions comprising bacterial strains
MD3209381T2 (en) Compositions comprising bacterial strains
MX2020003939A (en) Mdm2 inhibitors and therapeutic methods using the same.
CY1122227T1 (en) ADJUSTMENT OF SUPPLEMENT ACTIVITY
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
CO2020010956A2 (en) Compositions and methods for the treatment of cancer and immune disorders using veillonella bacteria
BR112018003269A2 (en) anti-dll3 drug-antibody conjugates and methods of use
CL2016002971A1 (en) Combination.
MD20170032A2 (en) Anti-TIGIT antibodies
EA201790737A1 (en) COMBINED THERAPY
GB2541571A (en) Pharmaceutical compositions
EA201991997A1 (en) COMBINED THERAPY
EA201690206A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
CL2018001108A1 (en) Compositions and methods for tumor transduction
BR112017004444A2 (en) new anti-mfi2 antibodies and methods of use
MX2017002489A (en) Human therapeutic agents.
TR201901348T4 (en) Pyrrolidinone derivatives as metap-2 inhibitors.
MX2018006249A (en) Novel anti-emr2 antibodies and methods of use.
EA201790312A1 (en) COMBINATION OF MEDICINES FOR THE TREATMENT OF MULTIPLE MYELOMA
EA201692534A1 (en) METHODS OF TREATMENT OF HYPOTHONY
EA201792571A1 (en) THERAPEUTIC APPLICATION OF L-4-CHLOROKINURENIN